In This Article:
Alkermes (NASDAQ:ALKS) Third Quarter 2024 Results
Key Financial Results
-
Revenue: US$378.1m (flat on 3Q 2023).
-
Net income: US$92.8m (up 94% from 3Q 2023).
-
Profit margin: 25% (up from 13% in 3Q 2023).
-
EPS: US$0.57 (up from US$0.29 in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Alkermes EPS Misses Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 2.9%.
Looking ahead, revenue is forecast to stay flat during the next 3 years compared to a 24% growth forecast for the Biotechs industry in the US.
Performance of the American Biotechs industry.
The company's shares are down 5.2% from a week ago.
Risk Analysis
You still need to take note of risks, for example - Alkermes has 1 warning sign we think you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.